Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Pancreatic Ductal Adenocarcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Pancreatic Cancer (499
)
Pancreatic Adenocarcinoma (81
)
Pancreatic Cancer (499
)
Pancreatic Adenocarcinoma (81
)
›
Associations
(133)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Pancreatic Ductal Adenocarcinoma
No biomarker
Pancreatic Ductal Adenocarcinoma
SBP-101
Sensitive: B - Late Trials
SBP-101
Sensitive
:
B
SBP-101
Sensitive: B - Late Trials
SBP-101
Sensitive
:
B
No biomarker
Pancreatic Ductal Adenocarcinoma
No biomarker
Pancreatic Ductal Adenocarcinoma
gemcitabine
Sensitive: B - Late Trials
gemcitabine
Sensitive
:
B
gemcitabine
Sensitive: B - Late Trials
gemcitabine
Sensitive
:
B
No biomarker
Pancreatic Ductal Adenocarcinoma
No biomarker
Pancreatic Ductal Adenocarcinoma
gemcitabine + capecitabine
Sensitive: B - Late Trials
gemcitabine + capecitabine
Sensitive
:
B
gemcitabine + capecitabine
Sensitive: B - Late Trials
gemcitabine + capecitabine
Sensitive
:
B
CCL11 overexpression
Pancreatic Ductal Adenocarcinoma
CCL11 overexpression
Pancreatic Ductal Adenocarcinoma
tertomotide
Sensitive: B - Late Trials
tertomotide
Sensitive
:
B
tertomotide
Sensitive: B - Late Trials
tertomotide
Sensitive
:
B
No biomarker
Pancreatic Ductal Adenocarcinoma
No biomarker
Pancreatic Ductal Adenocarcinoma
LSTA1
Sensitive: B - Late Trials
LSTA1
Sensitive
:
B
LSTA1
Sensitive: B - Late Trials
LSTA1
Sensitive
:
B
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: B - Late Trials
gemcitabine + albumin-bound paclitaxel
Sensitive
:
B
gemcitabine + albumin-bound paclitaxel
Sensitive: B - Late Trials
gemcitabine + albumin-bound paclitaxel
Sensitive
:
B
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: B - Late Trials
5-fluorouracil + oxaliplatin
Sensitive
:
B
5-fluorouracil + oxaliplatin
Sensitive: B - Late Trials
5-fluorouracil + oxaliplatin
Sensitive
:
B
No biomarker
Pancreatic Ductal Adenocarcinoma
No biomarker
Pancreatic Ductal Adenocarcinoma
atezolizumab + pelareorep
Sensitive: B - Late Trials
atezolizumab + pelareorep
Sensitive
:
B
atezolizumab + pelareorep
Sensitive: B - Late Trials
atezolizumab + pelareorep
Sensitive
:
B
NRG1 fusion
Pancreatic Ductal Adenocarcinoma
NRG1 fusion
Pancreatic Ductal Adenocarcinoma
MCLA-128
Sensitive: B - Late Trials
MCLA-128
Sensitive
:
B
MCLA-128
Sensitive: B - Late Trials
MCLA-128
Sensitive
:
B
No biomarker
Pancreatic Ductal Adenocarcinoma
No biomarker
Pancreatic Ductal Adenocarcinoma
aglatimagene besadenovec
Sensitive: B - Late Trials
aglatimagene besadenovec
Sensitive
:
B
aglatimagene besadenovec
Sensitive: B - Late Trials
aglatimagene besadenovec
Sensitive
:
B
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
ATM mutation
Pancreatic Ductal Adenocarcinoma
ATM mutation
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
BRCA1 mutation
Pancreatic Ductal Adenocarcinoma
BRCA1 mutation
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
olaparib
Sensitive: C1 - Off-label
olaparib
Sensitive
:
C1
KRAS G12C
Pancreatic Ductal Adenocarcinoma
KRAS G12C
Pancreatic Ductal Adenocarcinoma
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
KRAS mutation
Pancreatic Ductal Adenocarcinoma
KRAS mutation
Pancreatic Ductal Adenocarcinoma
pembrolizumab + trametinib
Sensitive: C2 – Inclusion Criteria
pembrolizumab + trametinib
Sensitive
:
C2
pembrolizumab + trametinib
Sensitive: C2 – Inclusion Criteria
pembrolizumab + trametinib
Sensitive
:
C2
CLDN18.2 positive
Pancreatic Ductal Adenocarcinoma
CLDN18.2 positive
Pancreatic Ductal Adenocarcinoma
CT041
Sensitive: C2 – Inclusion Criteria
CT041
Sensitive
:
C2
CT041
Sensitive: C2 – Inclusion Criteria
CT041
Sensitive
:
C2
KRAS mutation
Pancreatic Ductal Adenocarcinoma
KRAS mutation
Pancreatic Ductal Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Resistant: C2 – Inclusion Criteria
gemcitabine + albumin-bound paclitaxel
Resistant
:
C2
gemcitabine + albumin-bound paclitaxel
Resistant: C2 – Inclusion Criteria
gemcitabine + albumin-bound paclitaxel
Resistant
:
C2
HGF elevation
Pancreatic Ductal Adenocarcinoma
HGF elevation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Resistant: C3 – Early Trials
FOLFIRINOX
Resistant
:
C3
FOLFIRINOX
Resistant: C3 – Early Trials
FOLFIRINOX
Resistant
:
C3
MSI-L/dMMR
Pancreatic Ductal Adenocarcinoma
MSI-L/dMMR
Pancreatic Ductal Adenocarcinoma
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
MSI-L/dMMR
Pancreatic Ductal Adenocarcinoma
MSI-L/dMMR
Pancreatic Ductal Adenocarcinoma
ipilimumab
Sensitive: C3 – Early Trials
ipilimumab
Sensitive
:
C3
ipilimumab
Sensitive: C3 – Early Trials
ipilimumab
Sensitive
:
C3
MSI-L/dMMR
Pancreatic Ductal Adenocarcinoma
MSI-L/dMMR
Pancreatic Ductal Adenocarcinoma
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
PALB2 mutation
Pancreatic Ductal Adenocarcinoma
PALB2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
FOLFIRINOX
Sensitive
:
C3
FOLFIRINOX
Sensitive: C3 – Early Trials
FOLFIRINOX
Sensitive
:
C3
BRCA1 mutation + BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
BRCA1 mutation + BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
FOLFIRINOX
Sensitive
:
C3
FOLFIRINOX
Sensitive: C3 – Early Trials
FOLFIRINOX
Sensitive
:
C3
FANCF mutation
Pancreatic Ductal Adenocarcinoma
FANCF mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
FOLFIRINOX
Sensitive
:
C3
FOLFIRINOX
Sensitive: C3 – Early Trials
FOLFIRINOX
Sensitive
:
C3
MSH2 mutation
Pancreatic Ductal Adenocarcinoma
MSH2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
FOLFIRINOX
Sensitive
:
C3
FOLFIRINOX
Sensitive: C3 – Early Trials
FOLFIRINOX
Sensitive
:
C3
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
FOLFIRINOX
Sensitive
:
C3
FOLFIRINOX
Sensitive: C3 – Early Trials
FOLFIRINOX
Sensitive
:
C3
BRCA1 mutation
Pancreatic Ductal Adenocarcinoma
BRCA1 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
FOLFIRINOX
Sensitive
:
C3
FOLFIRINOX
Sensitive: C3 – Early Trials
FOLFIRINOX
Sensitive
:
C3
DDR
Pancreatic Ductal Adenocarcinoma
DDR
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive: C3 – Early Trials
olaparib
Sensitive
:
C3
olaparib
Sensitive: C3 – Early Trials
olaparib
Sensitive
:
C3
C3M/PRO-C3 ratio elevation
Pancreatic Ductal Adenocarcinoma
C3M/PRO-C3 ratio elevation
Pancreatic Ductal Adenocarcinoma
PEGPH20
Sensitive: C3 – Early Trials
PEGPH20
Sensitive
:
C3
PEGPH20
Sensitive: C3 – Early Trials
PEGPH20
Sensitive
:
C3
PALB2 mutation
Pancreatic Ductal Adenocarcinoma
PALB2 mutation
Pancreatic Ductal Adenocarcinoma
cisplatin + gemcitabine
Sensitive: C3 – Early Trials
cisplatin + gemcitabine
Sensitive
:
C3
cisplatin + gemcitabine
Sensitive: C3 – Early Trials
cisplatin + gemcitabine
Sensitive
:
C3
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
cisplatin + gemcitabine
Sensitive: C3 – Early Trials
cisplatin + gemcitabine
Sensitive
:
C3
cisplatin + gemcitabine
Sensitive: C3 – Early Trials
cisplatin + gemcitabine
Sensitive
:
C3
BRCA1 mutation
Pancreatic Ductal Adenocarcinoma
BRCA1 mutation
Pancreatic Ductal Adenocarcinoma
cisplatin + gemcitabine
Sensitive: C3 – Early Trials
cisplatin + gemcitabine
Sensitive
:
C3
cisplatin + gemcitabine
Sensitive: C3 – Early Trials
cisplatin + gemcitabine
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login